Twist Bioscience Corp (NASDAQ:TWST) CEO Emily M. Leproust has sold a total of 1,114 shares of company stock, a recent filing with the Securities and Exchange Commission revealed. The transaction, which took place on July 2, 2024, amounted to over $53,000 based on the price of $48.002 per share.
The sale was part of a "sell to cover" transaction, a common practice where shares are sold to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). This procedure is mandated by the issuer's equity incentive plans and is not indicative of discretionary trading by the reporting person.
Following this transaction, Leproust still holds a substantial number of shares in Twist Bioscience, amounting to 504,732 shares of common stock, according to the post-transaction amounts listed in the filing.
In addition to the sale, the filing also disclosed information about derivative securities in the form of employee stock options. These options, with varying exercise prices and expiration dates, represent the right to buy additional shares of Twist Bioscience Corp at predetermined prices. However, it's important to note that the options themselves have not been exercised or sold and therefore do not impact the total value of the recent transaction.
Investors often keep a close eye on insider transactions as they can provide insights into the executives' perspectives on the company's current valuation and future prospects. However, transactions related to tax obligations are typically viewed differently from open market buys or sells, which may more directly signal an insider's confidence in the company's performance.
Twist Bioscience specializes in synthetic biology and is known for its innovative work in DNA synthesis. The company's stock is publicly traded on the NASDAQ, and its financial performance is closely watched by investors interested in the biotechnology sector.
"In other recent news, Twist Bioscience Corporation has reported a significant 25% increase in revenue for the fiscal 2024 second quarter, amounting to $75.3 million. This growth was primarily driven by the company's synthetic biology product line and Next-Generation Sequencing (NGS) segment, leading to a gross margin exceeding expectations at 41%. The company anticipates a gross margin above 50% by the end of fiscal 2025. Twist Bioscience also expects its total revenue for fiscal 2024 to be between $300 million and $304 million, with a gross margin of 41.5% to 42%.
Furthermore, Twist Bioscience retained its Overweight rating from Barclays (LON:BARC), which sees an opportunity for the company in the wake of recent government inquiries into a competitor's business operations. The Select Committee on the Chinese Communist Party has sought information regarding GenScript, a competitor of Twist Bioscience, as part of the Biosecure Act. Barclays views this development as potentially advantageous for Twist Bioscience and other U.S.-based synthetic DNA suppliers.
These are recent developments highlighting the company's ongoing financial performance and market strategies. Despite reporting a net loss of $45.5 million for the quarter, Twist Bioscience remains optimistic about its market position, particularly in the biopharma sector."
InvestingPro Insights
As Twist Bioscience Corp (NASDAQ:TWST) navigates the complexities of the biotech sector, recent metrics from InvestingPro provide a snapshot of the company's financial health and market performance. With a market capitalization of $2.82 billion and a notable revenue growth of 21.79% over the last twelve months as of Q2 2024, the company is showing signs of expanding its market presence despite the challenges inherent in the industry.
InvestingPro Data reveals that while the company's P/E ratio stands at -14.39, reflecting market skepticism about its immediate profitability, Twist Bioscience has experienced a strong return over the last three months, with a 47.19% price total return. Additionally, the company's gross profit margin is at 38.29%, which suggests that it is maintaining a degree of cost efficiency in its operations.
Among the InvestingPro Tips, it's noted that analysts do not anticipate the company will be profitable this year, which aligns with the reported operating income margin of -70.14%. Moreover, the company's liquid assets exceed its short-term obligations, indicating a stable financial position for managing its debts in the near term. This information is particularly relevant for investors considering the recent insider transaction involving CEO Emily M. Leproust.
For those looking to delve deeper into Twist Bioscience's financials and market performance, additional InvestingPro Tips suggest stock price movements have been quite volatile, and the company does not pay a dividend to shareholders. This could be of interest to investors who prioritize growth potential or prefer to reinvest earnings back into the company. To access a full range of insights, investors are encouraged to explore InvestingPro, with the opportunity to use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. In total, there are 9 additional InvestingPro Tips available for Twist Bioscience, providing a comprehensive analysis of the company's financial standing and market activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.